Expand Document  |  Expand Chapter  |  Full TOC  |  Printable HTML version
WHO Expert Committee on Specifications for Pharmaceutical Preparations - WHO Technical Report Series, No. 902 - Thirty-sixth Report
(2002; 219 pages) View the PDF document
Table of Contents
View the documentWHO Expert Committee on Specifications for Pharmaceutical Preparations
View the document1. Introduction
Open this folder and view contents2. Quality control - specifications and tests
Open this folder and view contents3. Quality control - reference materials
Open this folder and view contents4. Quality control - pharmaceutical control laboratories
Open this folder and view contents5. Quality assurance - good manufacturing practices
Open this folder and view contents6. Quality assurance - inspection
Open this folder and view contents7. Quality assurance - packaging
Open this folder and view contents8. Quality assurance - general topics
Open this folder and view contents9. Nomenclature and computerized systems
Open this folder and view contents10. Regulatory issues
View the documentAcknowledgements
View the documentReferences
View the documentAnnex 1 - List of available International Chemical Reference Substances1
View the documentAnnex 2 - List of available International Infrared Reference Spectra
Open this folder and view contentsAnnex 3 - Good practices for national pharmaceutical control laboratories
View the documentAnnex 4 - Considerations for requesting analysis of drug samples1
View the documentAnnex 5 - Basic elements of good manufacturing practices in pharmaceutical production
Open this folder and view contentsAnnex 6 - Good manufacturing practices for sterile pharmaceutical products
Open this folder and view contentsAnnex 7 - Guidelines on pre-approval inspections
Open this folder and view contentsAnnex 8 - Quality systems requirements for national good manufacturing practice inspectorates
Open this folder and view contentsAnnex 9 - Guidelines on packaging for pharmaceutical products
View the documentAnnex 10 - Model certificate of analysis
View the documentAnnex 11 - Guidance on the selection of comparator pharmaceutical products for equivalence assessment of interchangeable multisource (generic) products
View the documentAnnex 12 - Guidelines on the use of International Nonproprietary Names (INNs) for pharmaceutical substances
View the documentSelected WHO Publications of Related Interest
View the documentBack Cover
 

Annex 2 - List of available International Infrared Reference Spectra

International Infrared Reference Spectra are established on the advice of the WHO Expert Committee on Specifications for Pharmaceutical Preparations. Full-scale reproductions of spectra produced from authenticated material on a suitable instrument are supplied for use in identification tests described in the specifications for quality control of drugs, published in The international pharmacopoeia or proposed in draft monographs.

Precise instructions for the preparation of spectra are given on the label of each reference spectrum. All International Infrared Reference Spectra are distributed together with a document giving further details on the use of such spectra, entitled “General recommendations for the preparation and use of infrared spectra in pharmaceutical analysis”.1

1 WHO Expert Committee on Specifications for Pharmaceutical Preparations. Thirty-fourth report. Geneva, World Health Organization, 1996, Annex 4 (WHO Technical Report Series, No. 863).

Orders for International Infrared Reference Spectra should be sent to:

WHO Collaborating Centre for Chemical Reference Substances
Apoteket AB
Produktion & Laboratorier Centrallaboratoriet, ACL
Prismavägen 2
S-141 75 Kungens Kurva
Sweden
Tel.: +46 8 466 1000
Fax: +46 8 740 6040
Email: who.apl@apoteket.se

The following International Infrared Reference Spectra are currently available from the Centre:

aceclidine salicylate
acetazolamide
allopurinol
amiloride hydrochloride
amitriptyline hydrochloride
ampicillin trihydrate
beclometasone dipropionate
benzylpenicillin potassium
biperiden
biperiden hydrochloride
bupivacaine hydrochloride
caffeine (anhydrous)
calcium folinate
carbidopa
chlorphenamine hydrogen maleate
clofazimine
cloxacillin sodium
colchicine
cytarabine
dexamethasone
dexamethasone acetate, monohydrate
dextromethorphan hydrobromide
diazepam
dicolinium iodide
dicoumarol
diethylcarbamazine dihydrogen citrate
diphenoxylate hydrochloride
erythromycin ethylsuccinate
erythromycin stearate
etacrynic acid
ethionamide
ethosuximide
furosemide
gallamine triethiodide
glibenclamide
haloperidol
hydrochlorothiazide
ibuprofen
imipramine hydrochloride
indometacin
isoniazid
lidocaine
lidocaine hydrochloride
lindane
metronidazole
miconazole nitrate
niclosamide
nicotinamide
noscapine
oxamniquine
papaverine hydrochloride
phenobarbital
phenoxymethylpenicillin calcium
phenytoin
primaquine phosphate
propylthiouracil
protionamide
pyrimethamine
salbutamol
salbutamol sulfate
sulfadimidine
sulfadoxine
sulfamethoxazole
sulfamethoxypyridazine
tiabendazole
trihexyphenidyl hydrochloride
trimethoprim
valproic acid
verapamil hydrochloride

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: August 29, 2014